AstraZeneca ENHERTU improves PFS in Phase III
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said ENHERTU significantly improved progression-free survival versus standard first-line treatment in the Phase III DESTINY-Lung04 lung cancer trial.

TV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said ENHERTU significantly improved progression-free survival versus standard first-line treatment in the Phase III DESTINY-Lung04 lung cancer trial.
Bitcoin (CRYPTO:BTC) started the new week trading at approximately US$63,300, recovering slightly after a decline of more than 3% over the previous week, whilst attempting to hold above the critical US$62,300 support level.
TTM Technologies (NASDAQ:TTMI) agreed to acquire Epiq Design Solutions for approximately $1.1 billion in cash to expand its integrated electronics portfolio.
HUTCHMED (NASDAQ:HCM) reported that ORPATHYS plus TAGRISSO significantly improved progression-free and overall survival versus platinum-based chemotherapy in its 338-patient Phase 3 SAFFRON trial.
Blockstream launched its swaps service in beta after Boltz suspended operations on 3 August.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said Enhertu significantly improved progression-free survival versus standard first-line treatment for advanced HER2-mutant non-small cell lung cancer.
Greenlane Holdings ended the second quarter with BERA holdings worth $16.4 million.
Euro Manganese (ASX:EMN) signed a non-binding term sheet with 6K Energy to supply high-purity electrolytic manganese metal from 2028.
Robert Kiyosaki said silver was his preferred metal as US public debt approached $40 trillion.
Kalshi was ordered to stop offering a broad range of prediction markets in Washington state after a judge rejected its federal pre-emption argument.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy